ofloxacin has been researched along with Skin Diseases in 11 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Skin Diseases: Diseases involving the DERMIS or EPIDERMIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin and sparfloxacin are active against pathogens frequently involved in community-acquired upper and lower respiratory tract infections, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydia pneumoniae." | 4.80 | Levofloxacin and sparfloxacin: new quinolone antibiotics. ( Chuck, SK; Jung, R; Martin, SJ; Messick, CR; Meyer, JM; Pendland, SL, 1998) |
| "Sarcoidosis is a chronic granulomatous disease for which there are limited therapeutic options." | 2.78 | Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. ( Aboud, C; Algood, H; Boyd, AS; Braun, N; Burke, VE; Drake, WP; Isom, J; Kaminski, N; King, LE; Oswald-Richter, K; Pandit, KV; Richmond, BW; Taylor, T; Yu, C, 2013) |
| "Both levofloxacin and TC/AC were well tolerated." | 2.70 | Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. ( Corrado, M; Fowler, CL; Graham, DR; Lucasti, C; Morgan, N; Nichols, RL; Talan, DA, 2002) |
| "To probe the pharmacokinetic basis for the use of levofloxacin for complicated skin and skin-structure infections (SSSIs) at a once-daily dosage of 750 mg by investigating its penetration into skin tissue." | 2.70 | Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses. ( Chen, A; Chow, AT; Fowler, C; Lattime, H; Morgan, N; Williams, RR; Wong, F, 2002) |
| " Although very useful agents, the fluoroquinolones as a class are associated with a number of adverse events, some with considerable clinical significance." | 2.46 | Safety profile of the fluoroquinolones: focus on levofloxacin. ( Liu, HH, 2010) |
| " Mean levels +/- standard deviation (in micrograms per milliliter) when measured by MBA after intravenous dosing were (postdose versus predose) 6." | 1.28 | High-pressure liquid chromatography and microbiological assay of serum ofloxacin levels in adults receiving intravenous and oral therapy for skin infections. ( Auten, GM; Bittner, MJ; Preheim, LC; Sookpranee, M; Sookpranee, T; Vibhagool, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drake, WP | 1 |
| Oswald-Richter, K | 1 |
| Richmond, BW | 1 |
| Isom, J | 1 |
| Burke, VE | 1 |
| Algood, H | 1 |
| Braun, N | 1 |
| Taylor, T | 1 |
| Pandit, KV | 1 |
| Aboud, C | 1 |
| Yu, C | 1 |
| Kaminski, N | 1 |
| Boyd, AS | 1 |
| King, LE | 1 |
| Patel, RR | 1 |
| Zirvi, M | 1 |
| Walters, RF | 1 |
| Kamino, H | 1 |
| Liu, HH | 1 |
| Graham, DR | 1 |
| Talan, DA | 1 |
| Nichols, RL | 1 |
| Lucasti, C | 1 |
| Corrado, M | 1 |
| Morgan, N | 2 |
| Fowler, CL | 1 |
| Zhang, ZY | 1 |
| Ying, ZW | 1 |
| Zhang, SY | 1 |
| Lin, JM | 1 |
| Iakovlev, VP | 1 |
| Svetukhin, AM | 1 |
| Blatun, LA | 1 |
| Ukhin, SA | 1 |
| Ludwig, RJ | 1 |
| Henke, U | 1 |
| Wolter, M | 1 |
| Walker, SL | 1 |
| Brandt, C | 1 |
| Wichelhaus, TA | 1 |
| Kramme, S | 1 |
| Lockwood, DN | 1 |
| Kaufmann, R | 1 |
| Martin, SJ | 1 |
| Meyer, JM | 1 |
| Chuck, SK | 1 |
| Jung, R | 1 |
| Messick, CR | 1 |
| Pendland, SL | 1 |
| Colsky, AS | 1 |
| Kirsner, RS | 1 |
| Kerdel, FA | 1 |
| Chow, AT | 1 |
| Chen, A | 1 |
| Lattime, H | 1 |
| Wong, F | 1 |
| Fowler, C | 1 |
| Williams, RR | 1 |
| Auten, GM | 1 |
| Preheim, LC | 1 |
| Sookpranee, M | 1 |
| Bittner, MJ | 1 |
| Sookpranee, T | 1 |
| Vibhagool, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of the Effects of Antibiotics on Sarcoidosis Pathogenesis[NCT01074554] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Multicenter, Randomized, Open-Label Study to Compare the Safety and Efficacy of i.v. And/Or Oral Levofloxacin With That of Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Bacterial Skin and Skin Struc[NCT00249197] | Phase 3 | 413 participants (Actual) | Interventional | 1997-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01074554)
Timeframe: Baseline to 8 weeks
| Intervention | mm (Median) |
|---|---|
| Antibiotic Regimen | -8.4 |
| Placebo Regimen | 0.07 |
Characterization of lesion severity was conducted using Modified Sarcoidosis Activity and Severity Index (SASI), measuring erythema, induration and desquamation. The modification was that the same scale was applied to any part of the body, instead of the face alone. The scale range is 0 (no problem) to 72 (very severe). (NCT01074554)
Timeframe: Baseline to 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Antibiotic Regimen | -2.9 |
| Placebo Regimen | -0.6 |
Number of patients with a decrease in Granuloma Burden (only in those patients having granulomas present at baseline biopsy) (NCT01074554)
Timeframe: Baseline to 8 weeks
| Intervention | participants (Number) |
|---|---|
| Antibiotic Regimen | 7 |
| Placebo Regimen | 0 |
3 reviews available for ofloxacin and Skin Diseases
| Article | Year |
|---|---|
Safety profile of the fluoroquinolones: focus on levofloxacin.
Topics: Adult; Aged, 80 and over; Anti-Bacterial Agents; Cardiovascular Diseases; Central Nervous System Dis | 2010 |
[Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Central Nervous System Diseases; Ciprofloxacin; Gastro | 2004 |
Levofloxacin and sparfloxacin: new quinolone antibiotics.
Topics: Absorption; Anti-Infective Agents; Bronchitis; Drug Interactions; Drug Resistance, Microbial; Fluoro | 1998 |
3 trials available for ofloxacin and Skin Diseases
| Article | Year |
|---|---|
Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Azithromycin; CD4-Positive T-Lymphocytes; | 2013 |
Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Clavulanic Acids; Drug Therapy | 2002 |
Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Female; Humans; Levofloxacin; Male; | 2002 |
5 other studies available for ofloxacin and Skin Diseases
| Article | Year |
|---|---|
Acquired perforating calcific collagenosis after topical calcium chloride exposure.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Betamethasone; Calcinosis; Calcium Chloride; Cicatr | 2010 |
[Observations on the efficacy of Botai ointment in treating dermatosis common among armed forces receiving at-sea training].
Topics: Adult; Dermatitis, Contact; Dermatomycoses; Dexamethasone; Drug Therapy, Combination; Eczema; Female | 2002 |
Persistence of peri-neural granulomas after successful treatment of leprosy.
Topics: Diagnosis, Differential; Drug Therapy, Combination; Granuloma; Humans; Leprostatic Agents; Leprosy; | 2007 |
Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Dermatitis; Drug Resistance, Microbial; | 1998 |
High-pressure liquid chromatography and microbiological assay of serum ofloxacin levels in adults receiving intravenous and oral therapy for skin infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacteriological Techniques; Chromatography, Hi | 1991 |